MedTrace Logo

Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making

NCT03413514 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-29

No results posted yet for this study

Summary

The purpose of the study is to evaluate the maximal cycle of effective neoadjuvant chemotherapy for resectable gastric cancer, to determine what is the best cycle of neoadjuvant chemotherapy for the patients who receive neoadjuvant chemotherapy.

Conditions

Interventions

DRUG

NACT

SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)

PROCEDURE

SDM

Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making

PROCEDURE

Surgery

Radical surgery with D2 lymph node dissection

DRUG

ACT

SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)

OTHER

Questionnaire

MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Ziyu Li, MD · Peking University Cancer Hospital & Institute

  • Jiafu Ji, MD,PHD · Peking University Cancer Hospital & Institute

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2019-01-03
Completion
2023-01-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413514 on ClinicalTrials.gov